Wijekoon Danushi, Chen Marcus Y, Hughes Yasmin, Fairley Christopher K, Bradshaw Catriona S, Ong Jason J, Aguirre Ivette, Chow Eric P F
Melbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.
School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.
J Infect Dis. 2025 Jul 30;232(1):e35-e42. doi: 10.1093/infdis/jiaf107.
Many international guidelines recommend routine treatment for individuals reporting sexual contact with sexual partners with chlamydia. In October 2019, the Melbourne Sexual Health Centre (MSHC) changed routine treatment of all chlamydia contacts to selective treatment, reserving same-day treatment for those testing positive, unless patients presented with symptoms or with specific reasons.
We conducted a before-and-after study among chlamydia contacts at MSHC by comparing 12 months before the "routine treatment" period (December 2018 to October 2019) and after the "selective treatment" period (November 2019 to December 2020).
Of the 2843 chlamydia contacts included in the analysis, chlamydia positivity was 31.9% (907/2843). The proportion of contacts who received treatment before test results decreased from 91.1% (1380/1515) to 55.6% (739/1328) (P < .0001). We reviewed 232 of the 739 chlamydia contacts in the selective period to determine reasons for treatment; 41.4% (96/232) were treated due to the presence of symptoms. The proportion of those who received treatment and later tested positive did not change between the 2 periods (3% [482/1380] vs 34.2% [253/739]; P = .750). The proportion of contacts who received unnecessary treatment (treated but tested negative) did not change between the 2 periods (65.1% [898/1380] vs 65.8% [486/739]; P = .750). Of the 60 who did not receive treatment but tested positive subsequently, 7 (11.7%) did not return for treatment, and it did not differ between the 2 periods (P = .370).
The selective treatment approach has reduced antibiotic consumption and likely decreased the overall workload of clinic staff by minimizing the need to treat all contacts.
许多国际指南建议,对于报告与衣原体感染性伴侣有性接触的个体进行常规治疗。2019年10月,墨尔本性健康中心(MSHC)将所有衣原体接触者的常规治疗改为选择性治疗,仅对检测呈阳性者进行当日治疗,除非患者出现症状或有特殊原因。
我们在MSHC对衣原体接触者进行了一项前后对照研究,比较了“常规治疗”期之前12个月(2018年12月至2019年10月)和“选择性治疗”期之后(2019年11月至2020年12月)的情况。
纳入分析的2843名衣原体接触者中,衣原体阳性率为31.9%(907/2843)。在检测结果出来之前接受治疗的接触者比例从91.1%(1380/1515)降至55.6%(739/1328)(P <.0001)。我们回顾了选择性治疗期739名衣原体接触者中的232名,以确定治疗原因;41.4%(96/232)因出现症状而接受治疗。两个时期接受治疗且后来检测呈阳性的比例没有变化(3% [482/1380] 对34.2% [253/739];P =.750)。两个时期接受不必要治疗(接受治疗但检测呈阴性)的接触者比例没有变化(65.1% [898/1380] 对65.8% [486/739];P =.750)。在60名未接受治疗但随后检测呈阳性的人中,7人(11.7%)未返回接受治疗,两个时期之间没有差异(P =.370)。
选择性治疗方法减少了抗生素的使用,并可能通过尽量减少对所有接触者进行治疗的需求,降低了临床工作人员的总体工作量。